The Epstein-Barr virus (EBV) latency C promoter drives expression of a family of viral proteins commonly targeted by CD8 cytotoxic T cells. These proteins are not generally expressed in African Burkitt's lymphoma and in EBV-associated Hodgkin's disease. The failure to express these proteins is almost certainly an important factor in the evasion of immunosurveillance by EBV-associated tumors. In a previous study, we have shown that transcriptional activation of the C promoter is inhibited by methylation of a particular CpG site upstream of the promoter that prevents binding of a cellular protein (CBFZ), and we have shown that this and adjacent CpG sites are methylated in a Burkitt's lymphoma cell line. In the present study, we show that CpG sites in the CBFL binding region are predominantly methylated in N HEALTHY Epstein-Barr virus (EBV)-seropositive volunteers, a potent immune response to EBV latency antigens is chronically maintained that prevents uncontrolled proliferation of EBV-infected B lymphocytes. Estimates of the frequency of cytotoxic T-cell (CTL) precursors specific for EBV antigens run as high as 1/400.' Most of the CTL response appears to be directed against the EB nuclear antigens (EBNAs), although EBNA-1 itself is apparently not recognized by CD8( +) cytotoxic T cell^.^.^ EBNA-2, EBNA-3A, EBNA-3B, and EBNA-3C are dominant targets on a range of HLA backgrounds, and more than 90% of healthy volunteers show cytotoxic T-cell responses to one or several of these antigens. We refer to this family of proteins as the immunodominant EBNAs. The EBV latency C promoter drives expression of the immunodominant EBNAs in EBVimmortalized lymphoblastoid cell lines. However, in Burkitt's lymphoma, the immunodominant EBNAs are generally not expressed, although some heterogeneity in patterns of antigen expression has recently been recognized. Similarly, in EBV-associated Hodgkin's disease, the C promoter is inactive and this family of proteins is not expressed.' Enforced silence of the C promoter may be a requirement for evasion of CD8(+) cytotoxic T-cell immune surveillance.
N HEALTHY Epstein-Barr virus (EBV)-seropositive vol-
unteers, a potent immune response to EBV latency antigens is chronically maintained that prevents uncontrolled proliferation of EBV-infected B lymphocytes. Estimates of the frequency of cytotoxic T-cell (CTL) precursors specific for EBV antigens run as high as 1/400.' Most of the CTL response appears to be directed against the EB nuclear antigens (EBNAs), although EBNA-1 itself is apparently not recognized by CD8( +) cytotoxic T cell^.^.^ EBNA-2, EBNA-3A, EBNA-3B, and EBNA-3C are dominant targets on a range of HLA backgrounds, and more than 90% of healthy volunteers show cytotoxic T-cell responses to one or several of these antigens. We refer to this family of proteins as the immunodominant EBNAs. The EBV latency C promoter drives expression of the immunodominant EBNAs in EBVimmortalized lymphoblastoid cell lines. However, in Burkitt's lymphoma, the immunodominant EBNAs are generally not expressed, although some heterogeneity in patterns of antigen expression has recently been recognized. Similarly, in EBV-associated Hodgkin's disease, the C promoter is inactive and this family of proteins is not expressed.' Enforced silence of the C promoter may be a requirement for evasion of CD8(+) cytotoxic T-cell immune surveillance.
The mechanism for this enforced silence of the C promoter is unknown, but methylation-mediated transcriptional repression has been implicated. Viral genomic hypermethylation has previously been identified in a Burkitt's-derived cell line (Rael) in which the C promoter is silent. This methylation can be reversed and C promoter driven antigen expression can be activated by treatment with 5-azacytidine, an inhibitor of DNA methyltran~ferase.~~ Sequence-specific DNA binding activities associated with this region of the C promoter have been previously characterized (Fig 1) . Transcription of the C promoter is activated by the interaction of a viral protein, EBNA-2, with a cellular sequence-specific DNA binding protein, CBFl ?-l2 A second sequence-specific cellular DNA binding activity footprints immediately downstream of CBFl and is referred to as CBF2. The in vitro binding activity of CBF2, but not of CBF1, is inhibited by CpG methylation at a specific CpG site. 7 The importance of CBF2 binding for C promoter transcriptional activity is highlighted by the observation that mutagenesis of this site markedly diminishes activity in a promoter-reporter assay. Thus, sensitivity to methylation-mediated transcriptional repression may be explained by inhibition of CBF2 binding. In the studies described here, we explore CpG methylation in the vicinity of the CBF2 binding site and associated C promoter transcription in primary tumor tissue.
MATERIALS AND METHODS
Tumor specimens. Burkitt's lymphoma tumor biopsies were collected from untreated patients with a histologic diagnosis of Burkitt's lymphoma through the National Cancer Institute's Burkitt Tumor Project located at the University of Ghana, Accra. Hodgkin's disease DNA samples were obtained through the Johns Hopkins Lymphoma DNA Bank. B-cell lymphoproliferative disease in a immunocompromised host consisted of excess material from a biopsy undertaken for diagnostic purposes in a patient with aplastic anemia treated with a combination of immunosuppressive drugs (antithymocyte globulin, cyclosporine A, and steroids). The tumor's histology was that of high-grade non-Hodgkin's lymphoma, with clonal rearrangement of the Ig heavy chain gene. After withdrawal of immunosuppression, the tumor regressed and the patient went into complete remission.
Reverse transcription-polymerase chain reaction (RT-PCR).
RNA was extracted from specimens of Burkitt's lymphoma and B- 
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EBNA-2:CBFl interaction is
unaffected; however, using rTth polymerase (Perkin Elmer, Norwalk, CT) according to the manufacturer's instructions. For EBNA-I and EBNA-3C. the S' U primer described by Sam et all3 was used in combination with 3' K1 or E3 primers of Qu and Rowe.14 For the C promoter, the 5' and 3' primers, respectively, were C2Wl and W1W2, which have been described by Qu and ROW^.'^ The RT reaction was performed at 60°C for 15 minutes. Amplification conditions were as follows: denature at 95°C for 1.5 minutes and 35 cycles at 95°C for 30 seconds, 60°C for 60 seconds, and 70°C for 60 seconds. The amplification products were electrophoresed and hybridized with internal oligonucleotide probes. EBER in situ hybridization. The localization of EBV to ReedSternberg cells of Hodgkin's disease specimens was determined using a standard digoxigenin-based in situ hybridization protocol for the detection of EBER-I in formalin-fixed paraffin-embedded tissue, as previously described." Positive controls consisted of known EBVpositive Hodgkin's disease specimens and B9S-8 cells fixed in formalin and embedded in paraffin.
Genomic sequencing. This was performed on extracted DNA using the bisulfite treatment method with minor modification^.'.'^ Briefly, 1 to 10 pg of genomic DNA was digested with EcoRI, alkali-denatured, neutralized, precipitated, and treated with sodium bisulfite/hydroquinone. After desalting procedures, PCR was performed and the amplification products were cloned and sequenced. The sequence of the region was also determined without bisulfite modification using the same procedure of PCR followed by cloning. The primers used have been previously described.' Cell lines. B95-8 is an EBV-transformed B-lymphoblastoid cell line. Rae1 is an EBV-associated Burkitt's derived cell line. These cell lines were maintained in RPM11640 supplemented with 10% fetal bovine serum and 1 mmoUL L-glutamine.
RESULTS
Endemic Burkitt's iymphomu.
On the basis of immunohistochemistry studies of primary tumor tissue and studies of transcription in Burkitt's cell lines, we anticipated that the C promoter was inactive in endemic Burkitt's lymphoma. To test this hypothesis, we extracted RNA from Burkitt's lymphoma specimens of five patients. To evaluate RNA preservation, we performed RT-PCR for p-actin and EBNA-1 transcripts. ,&Actin transcripts were detected in each specimen, whereas EBNA-1 transcripts were detected in only three of five tumor specimens (Fig 2) . This finding is consistent with the observation that, in cell lines, EBNA-I transcripts are relatively less abundant than &actin transcripts and suggests better preservation of RNA in the three specimens in which EBNA-1 transcripts were detected. There was no evidence of C promoter activity in any of the Burkitt's specimens.
Next, we undertook genomic sequencing to determine whether the CBF2 binding region of the C promoter was methylated. Bisulfite-treated DNA was PCR-amplified with strand-specific primers and the amplification products were cloned into plasmids. A total of 27 cloned inserts (5 to 7/ tumor) were sequenced and the methylation status at each of 9 CpG sites analyzed (Fig 3) . Of a total of 243 sites analyzed, 187 (77%) were methylated. The particular CpG site implicated in binding CBF2 (site no. 4) was methylated in 22 of 27 (81%) of cloned inserts, whereas a nearby CpG site (no. 2) was only methylated in 5 of 27 (19%) of cloned inserts. When site no. 2 was methylated, site no. 4 was always methylated (5/5 cloned inserts). Occasional cloned inserts (2/27 [7%]) showed a complete absence of methylation (Fig 3) . The fraction of sites methylated on a given plasmid insert was not evenly distributed, but was skewed toward all or none (Fig 4) .
Hodgkin 'S disease. EBV latency C promoter silence has previously been shown by RT-PCR in Hodgkin's di~ease.~ We sought to determine whether C promoter silence corresponded to methylation of the CBF2 binding region in viral DNA. Formalin-fixed paraffin-embedded archival diagnostic blocks from patients with Hodgkin's disease were screened by EBER in situ hybridization to identify EBV-associated tumors. Seven patients were identified with tumors in which EBV was present in Reed-Sternberg cells and their variants and tumor DNA was available in the Johns Hopkins Lymphoma Bank (data not shown). As with Burkitt's tumors. bisulfite-treated DNA was amplified. the products were cloned into plasmids. and the cloned inserts were sequenced (Fig 3) . The results were similar to those in Burkitt's lymphoma. A total of 39 cloned inserts were analyzed. Of 329 CpG sites analyzed. 302 (86%) were methylated. Site no. 4 Lymphoproliferative disease in immunocompromised patients is the one setting in which expression of the immunodominant EBNAs has been shown in tumor tissue. We studied one such case. RT-PCR showed C promoter activity (Fig 2) . Bisulfite genomic sequencing showed a nearly complete absence of methylation (Figs 3  and 4) . A total of 6 cloned inserts were studied. Of 54 CpG sites analyzed, only 3 (6%) were methylated. Sites no. 2 and 4 were never methylated.
DISCUSSION
We have shown CpG methylation in the CBF2 binding region of the EBV C promoter in tumors in which the C promoter is inactive and a corresponding lack of CpG methylation in a tumor in which the C promoter is active. These observations support the functional studies we have previously reported that show that ( I ) CBF2 binding is important for transcriptional activation of the C promoter, (2) CBF2 binding is inhibited by methylation, and (3) C promoter activity in a Burkitt's cell line can be activated by treatment with an inhibitor of DNA methyltransferase that results in demethylation of the CBF2 binding r e g i~n .~ Taken together, these observations suggest that methylation of the CBF2 binding region of the C promoter may be important in inhibiting CBF2 binding and preventing activation of or enforcing silence of the C promoter. Several possible roles for alterations in CpG methylation in tumorigenesis have been suggested previously. These include facilitation of C + T transition mutations, deregulation of growth genes by hypomethylation, and inactivation of tumor-suppressor genes by hypermethylati~n.'~ The contribution of methylation proposed here is similar to inactivaton of tumor-suppressor genes by hypermethylation insofar as methylation of transcriptional regulatory elements is central. However, there are two important differences. First, rather than reflecting a nonspecific effect of methylation on chromatin structure, we are proposing a specific effect mediated through a specific inhibition of binding. Second, in contrast to effects on tumorsuppressor genes that might manifest themselves in the growth or survival characteristics of cells grown in vitro, the survival advantage conferred by downregulation of the c promoter might only be manifest in the intact organism with an immune system.
Previous studies of transcriptional regulation in Burkitt's lymphoma have largely focused on cell lines. Early investigations suggested expression of many latency proteins in this tumor, including the immunodominant EBNAs, but subsequent analysis showed that the phenotype of the cell lines had drifted in culture." Patterns of viral antigen transcription differ markedly between early passage and late passage Burkitt's cell lines. Early passage Burkitt's lines tend to have a highly restricted pattern of antigen expression, expressing only a single viral antigen, EBNA-I, whereas late passage Burkitt's cell lines express at least 9 distinct viral proteins. The change in viral expression occurs in parallel with equally profound changes in cellular gene expression. It 
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Their ready availability in contrast to the lack of availability of snap-frozen or fresh tumor specimens from Africa has made them standard reagents in the study of EBV malignancy. However, our ignorance with regard to why these particular cell lines have not, to the best of our knowledge, altered their patterns of viral gene expression or cellular phenotype in culture underscores our uncertainty as to whether these cell lines truly reflect tumors in vivo. Niedobitek et all9 have recently shown in their analysis of fixed paraffin-embedded sections that patterns of antigen expression in endemic Burkitt's lymphoma were more complex than had been extrapolated from cell lines. They showed rare cells in some tumors expressing EBNA-2 and LMP-I, antigens that are not expressed in the Burkitt's cell lines thought to reflect the characteristics of tumor in vivo. These findings support the need to examine transcription patterns in primary tumor tissue. Our RT-PCR studies suggest that Rae1 and similar cell lines that show expression of EBNA-1 but lack expression of the immunodominant EBNAs do indeed preserve the transcription pattern of Burkitt's tumors in regard to the absence of C promoter activity. We presume that, in the tumors we examined as in the tumors described by Niedobitek et al," the rare tumor cell may have expressed immunodominant EBNAs, but that cells expressing these antigens are infrequent and, thus, not detected by RT-PCR. It might be noted in this regard that, although we had large pieces of frozen tumor tissue for this investigation, the tissue was not handled in a fashion that was amenable to immunohistochemistry, and corresponding fixed tissue was not available.
Just as extrapolation of patterns of gene expression from cell lines to tumor tissue is hazardous, similarly extrapolation of patterns of methylation from cell lines to tumor tissue is hazardous. Adaptation to cell culture is generally associated with methylation of CpG islands. This increase in methylation of cellular CpG islands with passage in tissue culture has been extensively documented in murine and human tissue culture systems, including B lymphocytes immortalized in vitro with EBV.2".2' Thus, CpG methylation detected in tumor cell lines may reflect methylation in primary tumor tissue or may reflect the impact of adaptation to cell culture conditions and studies of detailed patterns of CpG methylation in tumor-derived cell lines are therefore always suspect. To the best of our knowledge, the only previous study of methylation patterns of EBV in lymphoma tissue was limited to a Burkitt's-like lymphoma arising in a human immunodeficiency virus (H1V)-infected patient." This study showed methylation of viral DNA in the internal repeats as assessed by Southern blot hybridization after digestion with methylation sensitive and insensitive restriction enzymes. Our genomic sequencing studies are consistent with these previous results, but show methylation in a region of the C promoter upstream of the large internal repeats. The pattern of methylation we detected in Burkitt's tumor is similar to that in the Burkitt's cell line Rael, but is distinctive in two respects. First, some of the amplified viral genomes from Burkitt's tumors show less than complete methylation, particularly at site no. 2 (Figs 3 and 4) . Second, some amplified viral genomes from Burkitt's tumors show a complete absence of methylation. Both the incompletely methylated and completely unmethylated variants correspond to minor components of the total viral DNA extracted from the tumor, but similar heterogeneity is not present in amplified viral genomes from the Rael cell line.
What is the origin of the unmethylated genomes? They may derive from rare tumor cells that have entered the lytic cycle or rare tumor cells that have drifted to a more relaxed form of latency.'' Because fewer than 10% of cells can be shown to be either lytically infected or to be in a relaxed state of latency by immunohistochemistry, it seems unlikely that the majority of unmethylated viral genomes can be accounted for by cells that have drifted into a less-restricted form of latency. We favor the hypothesis that the unmethylated genomes correspond to lytically infected cells. The amplification of copy number that occurs in lytic infection means that, although lytically infected cells are rare, they may nonethless contribute significantly to the composition of total viral DNA extracted from tumor tissue.
The relevant issues in Hodgkin's disease differ in several respects. Whereas in Burkitt's lymphoma there exist a multitude of cell lines that appear to reflect primary tumor in their patterns of cellular and viral antigen expression, in Hodgkin's disease, the well-characterized cell lines are either lacking EBV or express antigens not detected by immunohistochemistry in primary tumor tissue.23 Furthermore, whereas something was known of the methylation status of the EBV genome in primary Burkitt's lymphoma tissue as a result of studies using methylation sensitive and insensitive restriction enzymes in combination with Southern blot hybridization, nothing was known of the methylation status of the EBV genome in Hodgkin's disease. We had attempted restriction enzyme-Southern blot analysis, but were unsuccessful in this approach, although we had previously used Southem blotting to detect viral DNA in Hodgkin's disease and to characterize its ~l o n a l i t y .~~-*~ Failure to characterize methylation patterns probably reflects the relative rarity of the EBVFor personal use only. on November 16, 2017. by guest www.bloodjournal.org From infected cell in Hodgkin's tumors compared with cell lines or other EBV-associated tumors combined with the small size of the particular restriction fragments of interest. Finally, in contrast to Burkitt's lymphoma, for which studies of viral transcription patterns in primary tumor tissue were not available, detailed studies of EBV transcription in Hodgkin's disease had previously been performed, and no C promoter activity was dete~ted.~ Hodgkin's disease and Burkitt's lymphoma differ in many ways, not the least of which is the distinctive myc-Ig chromosomal translocations in Burkitt's but not Hodgkin's tumors and the consistent high-level expression of the EBV latency membrane protein-l (LMP-1) in Hodgkin's but not in Burkitt's tumors. Although the C promoter is off in both tumors, it is of interest that patterns of methylation differ somewhat. In Hodgkin's disease, all the CpG sites studied were predominantly methylated, whereas in Burkitt's tumors, site no. 2 was predominantly unmethylated. The functional significance of this observation remains to be determined. As in Burkitt's tumors, a few cloned inserts from Hodgkin's disease are incompletely methylated and a few completely lack methylation. The explanation for the presence of unmethylated genomes may again relate to rare lytically infected cells that have been recognized in Hodgkin's di~ease.'~ In contrast to the situation with Burkitt's lymphoma, the presence of unmethylated viral genomes is unlikely to represent drift to a less restricted pattern of latent gene expression in vivo, because expression of the immunodominant EBNAs has never been recognized in Hodgkin's tumor cells, although many investigators, including ourselves, have looked carefully for the occasional cell that might have drifted.
Unlike Burkitt's and Hodgkin's disease, expression of the immunodominant EBNAs is well recognized in B-cell lymphoproliferative disease arising in immunosuppressed hosts. The C promoter activity and absence of methylation observed in the case of EBV-associated lymphoproliferative disease arising in an iatrogenically immunosuppressed patient show that the C promoter may be active and need not be methylated in vivo. We note that, in this regard, the case of B-cell lymphoproliferative disease arising in the immunocompromised host resembles an EBV-immortalized lymphoblastoid cell line. The possibility that sensitivity to immune manipulations is associated with C promoter-driven expression of the immunodominant EBNAs is emphasized by observations suggesting that, in organ transplant recipients in general, as in this case, immune reconstitution is often associated with regression of lymphoproliferative disease. This has been well documented after withdrawal or reduction of immunosuppressive therapy in solid organ transplant recipientsz8 or after donor lymphocyte infusion in allogeneic bone marrow transplant recipient^.'^ Most recently, infusion of EBV-specific donor T cells in the setting of allogeneic bone marrow transplantation has led to tumor regre~sion.~' These observations suggest that C promoter activity will only be demonstrable in immunocompromised patients.
De novo methylation of foreign DNA has been viewed as a defense mechanism that results in the neutralization of potentially damaging DNA sequence^.^'^^^ It is ironic that methylation in EBV-associated tumors may facilitate the evasion of immune surveillance. The possible contribution of methylation to lymphomagenesis is important not only for understanding the pathogenesis of these tumors, but also may have therapeutic import. Several inhibitors of DNA methyltransferase are being investigated in clinical trials as antineoplastic agents. In vitro, they are active in reversing methylation in the CBF2 binding region of the C promoter after a single exposure at clinically achievable levels, with resultant activation of C promoter expression of immunodominant antigens. A similar effect in vivo might render these tumors susceptible to cytotoxic T cells. 
